Derbal Youcef
Ted Rogers School of Information Technology Management, Toronto Metropolitan University, Toronto, ON, Canada.
Cancer Control. 2025 Jan-Dec;32:10732748251349919. doi: 10.1177/10732748251349919. Epub 2025 Jun 18.
Adaptive combination therapy is deemed the most intuitive strategy to thwart therapeutic resistance through dynamic treatment tuning that accounts for cancer evolutionary dynamics. However, higher accuracy and reliability of treatment response predictions would be needed, in addition to the need for clinically feasible models of adaptive combination therapy that consider newly approved therapeutics and the growing multimodal data being available about cancer. Grounded in nonlinear system control theory, this review offers a perspective on exploiting GenAI learning and inferencing capabilities to predict treatment response and recommend treatments in the context of adaptive cancer therapy. Results from nonlinear system identification, control theory and deep learning are integrated within an adaptive cancer control framework to leverage the continuously expanding data about cancer and its treatment towards GenAI-enhanced adaptive therapy. The resulting models and their analysis contribute to a much-needed conceptual clarity about the research and translational pathways that would be needed to realize GenAI-assisted cancer treatments. In particular, they underscore that access to clinical data, deep learning opacity, and clinical validation present critical challenges that require adequate attention to pave the way towards acceptance and integration of GenAI in real-world oncology workflows.
适应性联合疗法被认为是通过动态调整治疗方案来应对治疗耐药性的最直观策略,这种动态调整考虑了癌症的进化动态。然而,除了需要考虑新批准的治疗方法以及越来越多关于癌症的多模态数据的临床可行的适应性联合疗法模型外,还需要更高的治疗反应预测准确性和可靠性。基于非线性系统控制理论,本综述提供了一个视角,即在适应性癌症治疗背景下,利用生成式人工智能(GenAI)的学习和推理能力来预测治疗反应并推荐治疗方案。非线性系统识别、控制理论和深度学习的结果被整合到一个适应性癌症控制框架中,以利用不断扩展的关于癌症及其治疗的数据,实现基于GenAI的增强型适应性治疗。由此产生的模型及其分析有助于对实现GenAI辅助癌症治疗所需的研究和转化途径形成急需的概念清晰性。特别是,它们强调获取临床数据、深度学习不透明性和临床验证是关键挑战,需要给予充分关注,为GenAI在现实世界肿瘤学工作流程中的接受和整合铺平道路。